TNF and obesity due to melanocortin 4 receptor deficiency: On meta-analysis, across included IMIDs and across all anti-TNF agents, obesity was associated with 60% higher odds of failure of index anti-TNF therapy (OR, 1.60; 95% CI, 1.39–1.83), with substantial heterogeneity (I2 = 71%).[14, 26–33, 40–80]